HC Wainwright Predicts Increased Earnings for Scholar Rock

Scholar Rock Holding Corporation (NASDAQ:SRRK) – Equities research analysts at HC Wainwright upped their FY2027 earnings per share (EPS) estimates for Scholar Rock in a note issued to investors on Monday, January 26th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($2.28) for the year, up from their previous forecast of ($2.39). HC Wainwright has a “Buy” rating and a $58.00 price target on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Scholar Rock’s FY2028 earnings at ($0.92) EPS and FY2029 earnings at $0.17 EPS.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.02). During the same quarter in the previous year, the company earned ($0.66) EPS.

Several other brokerages have also weighed in on SRRK. Wolfe Research began coverage on Scholar Rock in a report on Tuesday, November 18th. They set an “outperform” rating and a $42.00 price objective for the company. Truist Financial cut their price target on shares of Scholar Rock from $54.00 to $44.00 and set a “buy” rating for the company in a report on Monday, October 20th. JPMorgan Chase & Co. raised their target price on shares of Scholar Rock from $46.00 to $47.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a research note on Thursday, January 22nd. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $50.00 price objective on shares of Scholar Rock in a research report on Friday, November 14th. Four analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $51.14.

Scholar Rock Price Performance

Shares of NASDAQ SRRK opened at $43.99 on Wednesday. The company has a market capitalization of $4.49 billion, a PE ratio of -13.97 and a beta of 0.63. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.41. The stock’s 50 day moving average price is $43.98 and its 200-day moving average price is $37.42. Scholar Rock has a twelve month low of $22.71 and a twelve month high of $48.28.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Ramirez Asset Management Inc. bought a new position in Scholar Rock during the 3rd quarter valued at about $37,000. Penserra Capital Management LLC purchased a new position in shares of Scholar Rock during the third quarter valued at approximately $56,000. Bessemer Group Inc. grew its stake in shares of Scholar Rock by 970.0% during the third quarter. Bessemer Group Inc. now owns 2,322 shares of the company’s stock valued at $86,000 after buying an additional 2,105 shares during the last quarter. Strs Ohio purchased a new stake in shares of Scholar Rock in the first quarter worth approximately $77,000. Finally, Elevation Point Wealth Partners LLC bought a new stake in shares of Scholar Rock during the 2nd quarter worth approximately $94,000. 91.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Scholar Rock

In other news, CFO Vikas Sinha sold 16,755 shares of Scholar Rock stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $42.70, for a total transaction of $715,438.50. Following the transaction, the chief financial officer owned 583,245 shares in the company, valued at $24,904,561.50. This trade represents a 2.79% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Akshay Vaishnaw sold 20,438 shares of the company’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total value of $872,702.60. Following the completion of the sale, the insider owned 595,767 shares of the company’s stock, valued at approximately $25,439,250.90. The trade was a 3.32% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 305,687 shares of company stock worth $13,540,573. Insiders own 13.30% of the company’s stock.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).